HighTower Advisors
NUVB icon

HighTower Advisors’s Nuvation Bio NUVB Stock Holding History

HighTower Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Buy
28,198
+5,741
+26% +$32K ﹤0.01% 3600
2025
Q4 		$201K Buy
22,457
+2,007
+10% +$12.4K ﹤0.01% 3374
2025
Q3 		$75.7K Buy
20,450
+10,000
+96% +$27.3K ﹤0.01% 3580
2025
Q2 		$20.4K Buy
+10,450
New +$21.8K ﹤0.01% 3615

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HighTower Advisors's NUVB Position: Q1 2026 in Review

HighTower Advisors increased its Nuvation Bio (NUVB) stake by 26% in Q1 2026, buying an estimated $32K and bringing the position to 28,198 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #3600.

HighTower Advisors first reported a position in NUVB in Q2 2025 and has held it in 4 quarters since. The position peaked at $201K in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • HighTower Advisors held 28,198 shares of Nuvation Bio worth $121K as of Q1 2026.
  • HighTower Advisors bought 5,741 Nuvation Bio shares in Q1 2026, an estimated $32K.
  • Nuvation Bio made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3600 holding.
  • HighTower Advisors first reported a position in Nuvation Bio in Q2 2025 and has held it in 4 quarters since.
  • HighTower Advisors's Nuvation Bio position peaked at $201K in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.